Strong SME Pharma IPO Launch
Asston Pharmaceuticals from Navi Mumbai is launching its SME IPO from July 9 to July 11, aiming to raise ₹27.56 crore. Priced between ₹115 and ₹123 per share, with a minimum investment of ₹2.46 lakh, the IPO targets both retail and institutional investors.
Financial Performance
- Revenue nearly doubled to ₹25.61 crore in FY2025, up from ₹15.84 crore in FY2024.
- Net profit increased sharply to ₹4.33 crore, compared to ₹1.36 crore in FY2024.
- Strong return on net worth (around 40%) and earnings per share of ₹6.90.
Use of Funds and Capacity
- IPO proceeds will fund equipment upgrades, working capital, and debt repayment.
- Manufacturing facility is WHO-GMP certified and produces millions of tablets and syrups monthly.
- Exports focus on emerging markets in Africa, with increasing contract manufacturing opportunities.
IPO Structure and Outlook
- Fresh issue of 22.41 lakh shares; 50% reserved for institutional investors, 35% for retail, 15% for high-net-worth individuals.
- Anchor investors have already committed close to ₹8 crore, with a 30 to 90-day lock-in period.
- Grey market premium suggests positive listing prospects.
This IPO is a solid entry point into a fast-growing SME with strong financials and export potential. Investors should monitor liquidity and market reception post-listing.